Abstract 386P
Background
Searching for specific targets in cancer diagnosis and treatment is one of the most important problems in clinical oncology. We put forward a new concept of the emergence of tumor-specific epitopes of integral membrane proteins by changing their topology under mutations, glycosylation and tumor conditions including low pH and hypoxia on the model of Na-dependent phosphate-cotransporter NaPi2b. NaPi2b (SLC34A2, NaPi-IIb, NPT2b) belongs to the SLC34A2 transporters family and is involved in maintaining phosphate homeostasis in the human body. NaPi2b express in a number of normal and malignant tissues, including ovarian, breast and triple-negative breast cancer. It is an integral membrane protein with a large extramembrane domain 4 (EMD4, 234-362 aa), 8 transmembrane domains, N - and C - ends located in the cytoplasm.
Methods
We have cloned the epitope for antibodies MX35 and L2 (20/3) within 311-340 aa region of NaPi2b, which recognition depends on disulfide bonds, glycosylation and is canceled by the mutation at the T330V position. Topology of the protein undergoing significant changes in hypoxia and low pH conditions.
Results
N-terminal domain of NaPi2b can be localized outside the cells during hypoxia and low pH and return to its primary topology at the inner leaflet membrane in normoxia conditions. This reorientation makes it as a potential tumor-specific domain.
Conclusions
The obtained data are of both fundamental and applied importance in the development of new targeted antitumor drugs of high specificity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kazan Federal University.
Funding
Russian Government Program of Competitive Growth of KFU.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract
371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
Presenter: Rajnish Nagarkar
Session: Poster display session
Resources:
Abstract
372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
Presenter: Yiyu Shen
Session: Poster display session
Resources:
Abstract
373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
Presenter: Aaron Tan
Session: Poster display session
Resources:
Abstract
374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)
Presenter: Nir Peled
Session: Poster display session
Resources:
Abstract
375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Presenter: Huixin Lin
Session: Poster display session
Resources:
Abstract
376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Presenter: Prasanta Dash
Session: Poster display session
Resources:
Abstract
377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
Presenter: Chia Wei Lim
Session: Poster display session
Resources:
Abstract
379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
Presenter: Padmaj Kulkarni
Session: Poster display session
Resources:
Abstract